Werewolf Therapeutics, Inc. (HOWL)Healthcare | Biotechnology | Watertown, United States | NasdaqCM
0.99 USD
+0.01
(0.947%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 1.00 +0.01 (0.898%) ⇧ (Oct. 13, 2026, 7:47 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:59 a.m. EDT
The investment case here is bifurcated between a speculative gamble and a fundamental reality check. On the short end, the options market is screaming for a moonshot; the concentration of open interest in far-out strikes ($2.50) indicates traders are betting on a binary event or a sudden re-rating that ignores current valuation. However, the long-term outlook is dire. The company has suffered four consecutive years of declining annual returns, with the stock down nearly 90% over the last four years. Fundamentals are broken: negative earnings, negative free cash flow, and negative gross margins indicate a business model that is currently burning capital without generating value. While the balance sheet shows some liquidity, the trajectory is unmistakably downward. The lack of a dividend reflects the company's need to retain cash for operations rather than returning value. Investors here are either buying a lottery ticket on a specific catalyst or ignoring the structural deterioration of the business. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.599077 |
| AutoARIMA | 0.601758 |
| MSTL | 0.619502 |
| AutoTheta | 0.669531 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 40.78 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.030 |
| Excess Kurtosis | -1.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.439 |
| Market Cap | 48,168,936 |
| Forward P/E | -1.68 |
| Beta | 0.51 |
| Profit Margins | -164.82% |
| Website | https://werewolftx.com |
As of Oct. 10, 2026, 5:59 a.m. EDT: Speculators are overwhelmingly positioning for a massive upside move, evidenced by heavy open interest in deep out-of-the-money calls (strikes $2.50+) across multiple expirations, while put activity is negligible. This 'lottery ticket' style positioning suggests a belief in a binary event or catalyst that could drive the price significantly higher, despite the lack of traditional bullish volume in near-term ATM calls.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.41197604 |
| Address1 | 200 Talcott Ave |
| Address2 | 2nd Floor |
| All Time High | 23.99 |
| All Time Low | 0.27 |
| Ask | 1.2 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 561,320 |
| Average Daily Volume3 Month | 6,794,343 |
| Average Volume | 6,794,343 |
| Average Volume10Days | 561,320 |
| Beta | 0.511 |
| Bid | 0.651 |
| Bid Size | 2 |
| Book Value | 0.335 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9911 |
| Current Ratio | 2.911 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.0101 |
| Day Low | 0.97 |
| Display Name | Werewolf Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,501,000 |
| Earnings Timestamp End | 1,793,363,400 |
| Earnings Timestamp Start | 1,793,363,400 |
| Ebitda | -21,921,000 |
| Ebitda Margins | -1.04386 |
| Enterprise To Ebitda | -1.194 |
| Enterprise To Revenue | 1.247 |
| Enterprise Value | 26,179,534 |
| Eps Current Year | -0.89 |
| Eps Forward | -0.59 |
| Eps Trailing Twelve Months | -0.73 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.79486 |
| Fifty Day Average Change | 0.19624001 |
| Fifty Day Average Change Percent | 0.24688625 |
| Fifty Two Week Change Percent | -41.197605 |
| Fifty Two Week High | 1.83 |
| Fifty Two Week High Change | -0.8389 |
| Fifty Two Week High Change Percent | -0.4584153 |
| Fifty Two Week Low | 0.27 |
| Fifty Two Week Low Change | 0.7211 |
| Fifty Two Week Low Change Percent | 2.6707406 |
| Fifty Two Week Range | 0.27 - 1.83 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,789,400,000 |
| Float Shares | 45,379,864 |
| Forward Eps | -0.59 |
| Forward P E | -1.6798306 |
| Free Cashflow | -12,233,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Fullday Change | 0.01819998 |
| Fullday Change Percent | 1.853736 |
| Fullday Price | 0.9911 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.2469 |
| Gross Profits | -5,185,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06624 |
| Held Percent Institutions | 0.39215 |
| Implied Shares Outstanding | 48,601,487 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. |
| Long Name | Werewolf Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 48,168,936 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_560735713 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -34,613,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 48,086,311 |
| Number Of Analyst Opinions | 3 |
| Open | 1.0 |
| Operating Cashflow | -30,148,000 |
| Operating Margins | 0.40652 |
| Phone | 617 952 0555 |
| Post Market Change | 0.008899987 |
| Post Market Change Percent | 0.89799076 |
| Post Market Price | 1.0 |
| Post Market Time | 1,791,935,258 |
| Previous Close | 0.9818 |
| Price Eps Current Year | -1.1135955 |
| Price Hint | 4 |
| Price To Book | 2.9585075 |
| Price To Sales Trailing12 Months | 2.2937589 |
| Profit Margins | -1.6482401 |
| Quick Ratio | 2.796 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00929999 |
| Regular Market Change Percent | 0.947239 |
| Regular Market Day High | 1.0101 |
| Regular Market Day Low | 0.97 |
| Regular Market Day Range | 0.97 - 1.0101 |
| Regular Market Open | 1.0 |
| Regular Market Previous Close | 0.9818 |
| Regular Market Price | 0.9911 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 353,193 |
| Return On Assets | -0.27387 |
| Return On Equity | -1.19859 |
| Revenue Per Share | 0.439 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 48,601,487 |
| Shares Percent Shares Out | 0.0517 |
| Shares Short | 2,511,400 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,668,357 |
| Short Name | Werewolf Therapeutics, Inc. |
| Short Percent Of Float | 0.0625 |
| Short Ratio | 3.03 |
| Source Interval | 15 |
| State | MA |
| Symbol | HOWL |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 21,987,000 |
| Total Cash Per Share | 0.452 |
| Total Debt | 0 |
| Total Revenue | 21,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.654215 |
| Two Hundred Day Average Change | 0.33688504 |
| Two Hundred Day Average Change Percent | 0.51494545 |
| Type Disp | Equity |
| Volume | 353,193 |
| Website | https://werewolftx.com |
| Zip | 2,472 |